SEC Filings

S-1
AVEXIS, INC. filed this Form S-1 on 01/15/2016
Entire Document
 

Table of Contents


AveXis, Inc.

Consolidated Statements of Operations and Comprehensive Loss

 
  Years Ended
December 31,
  Nine Months Ended
September 30,
 
 
 
2013
 
2014
 
2014
 
2015
 
 
   
   
  (unaudited)
 

Revenue

  $   $   $   $  

Operating expenses:

                         

General and administrative

    1,834,368     1,869,899     1,601,301     6,651,233  

Research and development

    362,609     13,550,422     10,167,011     18,756,214  

Total operating expenses

    2,196,977     15,420,321     11,768,312     25,407,447  

Loss from operations

    (2,196,977 )   (15,420,321 )   (11,768,312 )   (25,407,447 )

Interest expense (income)

    16,907     131,527     132,670     (94,410 )

Loss from continuing operations, before income taxes

    (2,213,884 )   (15,551,848 )   (11,900,982 )   (25,313,037 )

Income tax expense (benefit)

                 

Loss from continuing operations

    (2,213,884 )   (15,551,848 )   (11,900,982 )   (25,313,037 )

Loss from discontinued operations, net of tax

    475,530     8,729     8,729      

Loss from sale of discontinued operations, net of tax

        145,199     145,199      

Net loss and comprehensive loss

  $ (2,689,414 ) $ (15,705,776 ) $ (12,054,910 ) $ (25,313,037 )

Basic and diluted net loss per common share from continuing operations (Note 13)

  $ (0.49 ) $ (3.28 ) $ (2.55 ) $ (4.96 )

Basic and diluted net loss per common share from discontinued operations (Note 13)

    (0.11 )   (0.03 )   (0.03 )    

Basic and diluted net loss per common share (Note 13)

  $ (0.60 ) $ (3.31 ) $ (2.58 ) $ (4.96 )

Weighted-average basic and diluted common shares outstanding

    4,513,712     5,011,887     5,017,190     5,103,607  

Pro forma basic and diluted net loss per common share (unaudited) (Note 13)

        $ (2.33 )       $ (2.87 )

Pro forma weighted-average basic and diluted common shares outstanding (unaudited) (Note 13)

          6,745,954           8,825,900  

The accompanying notes are an integral part of these consolidated financial statements.

F-5



© AveXis, Inc. All Rights Reserved.